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Abstract
Hereditary and sporadic cerebellar ataxias represent a vast and still growing group of diseases 
whose diagnosis and differentiation cannot only rely on clinical evaluation. Brain imaging 
including magnetic resonance (MR) and nuclear medicine techniques allows for characterization 
of structural and functional abnormalities underlying symptomatic ataxias. These methods thus 
constitute a potential source of radiological biomarkers, which could be used to identify these 
diseases and differentiate subgroups of them, and to assess their severity and their evolution. Such 
biomarkers mainly comprise qualitative and quantitative data obtained from MR including proton 
spectroscopy, diffusion imaging, tractography, voxel-based morphometry, functional imaging 
during task execution or in a resting state, and from SPETC and PET with several radiotracers. In 
the current article, we aim to illustrate briefly some applications of these neuroimaging tools to 
evaluation of cerebellar disorders such as inherited cerebellar ataxia, fetal developmental 
malformations, and immune-mediated cerebellar diseases and of neurodegenerative or early-
developing diseases, such as dementia and autism in which cerebellar involvement is an emerging 
feature. Although these radiological biomarkers appear promising and helpful to better understand 
ataxia-related anatomical and physiological impairments, to date, very few of them have turned 
out to be specific for a given ataxia with atrophy of the cerebellar system being the main and the 
most usual alteration being observed. Consequently, much remains to be done to establish 
sensitivity, specificity, and reproducibility of available MR and nuclear medicine features as 
diagnostic, progression and surrogate biomarkers in clinical routine.
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 Introduction
Neuroimaging, including magnetic resonance imaging and single-photon emission computed 
tomography (SPECT)/positron emission tomography (PET), provides several and potential 
valuable biomarkers for diagnosis, prognosis, and follow-up of the course of cerebellar 
diseases. Conventional MRI sequences (T1, T2, T2*, FLAIR, STIR, diffusion, magnetic 
susceptibility, angiography) supply macroscopic clues for anatomical localization and 
diagnosis of a wide range of cerebellar alteration (for example: malformations, tumor, 
stroke, infection, and inflammation) including especially recessively and X-linked inherited 
ataxias. However, these MRI sequences can fail to detect subtle histological or biochemical 
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alteration, to differentiate properly subtypes of a given disease, and to establish robust 
anatomoclinical correlations. This is particularly the case for cerebellar ataxias and some 
neurodegenerative and neurodevelopmental diseases in which also the cerebellum appears to 
be affected [1, 2]. SPECT/PET using radiotracers of perfusion and glucose metabolism 
primarily contribute to search for brain hypoperfusion or hypometabolism [1]. 
Unconventional MRI techniques and utilization of more specific SPECT or PET radiotracers 
may widen the scope of neuroimaging in ataxia diseases and partly overcome some of the 
above limitations. First, unconventional MRI allows a thorough qualitative and quantitative 
characterization not only of gross anatomical alterations of the cerebellar system using, for 
instance, volume-based morphometry (VBM), but also of cerebellar microstructural tissue 
organization with measurement of the apparent diffusion coefficient (ADC) in diffusion-
weighted imaging (DWI) and with tractography performed on diffusion tensor imaging 
(DTI), which can compute anatomical bundles composing the white matter. Second, mono- 
and multi-voxel proton spectroscopy can identify biochemical alterations of the white and 
gray matter measuring different molecules such as N-acetyl-aspartate (neuronal biomarker), 
choline (membrane biomarker) myo-inositol (gliosis biomarker) or lactate (anaerobic 
metabolism biomarker). Third, several radiotracers can be utilized in nuclear medicine to 
detect or track specific regional dysfunctions, as that of the nigrostriatal pathway, and to 
clarify their underlying physiopathological mechanisms. Fourth, functional MR imaging 
during task execution or in a resting state may estimate disease-related functional alterations 
and reorganization (neuroplasticity) of the whole cerebellar system with potential correlation 
with clinical deficits and recovery. Fifth, pre- and postnatal ultrasound and MRI enable to 
follow and to detect early fetal developmental anomalies.
In the current article, we aim to illustrate briefly some applications of these neuroimaging 
tools, especially unconventional MRI techniques and SPECT/PET, in the evaluation of 
cerebellar disorders such as cerebellar ataxia (see Sections 1 and 2), fetal developmental 
malformations (see Section 3), autosomal dominant spinocerebellar ataxia (see Section 4), 
immune-mediated cerebellitis (see Section 5) and to characterization of cerebellar 
involvement in neurodegenerative diseases as dementia (see Section 6) and autism (see 
Section 7), recessive and X-linked hereditary ataxias (see Section 8), metabolic ataxias in 
children (see Section 9), and multiple systems atrophy and sporadic adult-onset ataxia of 
unknown etiology (see Section 10). Apart from macroscopic cerebellar disorganization due 
to developmental malformations, the most frequent alteration observed in MRI consists of 
regional atrophy mainly affecting more or less specific cerebellar lobes/lobules, pons 
(spinocerebellar ataxia (SCA), dementia, autism) and striatum (SCA1 and SCA3). Other 
alterations, sometimes in association with regional atrophy include: (1) microstructural 
abnormalities such as increased ADC in DWI and decreased fractional anisotropy (FA) in 
DTI (SCAs and Friedreich's ataxia), (2) decreased or increased cerebellar perfusion or 
metabolism (dementia, paraneoplastic syndrome, post-infection cerebellitis, multi system 
atrophy—cerebellar type, pure cerebellar ataxia) in SPECT or PET, and (3) proton MR 
spectroscopy alterations such as reduction of N-acetyl-aspartate (NAA) in gluten ataxia and 
SCAs. Functional connectivity of motor and cognitive cerebello-cortical networks proved to 
be altered in SCA17. Interestingly, presymptomatic carriers of several SCA subtypes 
exhibited nigrostriatal dysfunction and cerebellar hypometabolism. Nevertheless, no 
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biomarker turns out to be specific of a given pathology. Furthermore, some anatomoclinical 
correlation exist, for example, between specific atrophy of the anterior or posterior lobes and 
motor and neuropsychological atrophy (SCA, dementia) respectively, between increased 
ADC and clinical dysfunction (SCA1 and SCA2) or mean diffusivity (MD) increase and 
fractional anisotropy (FA) decrease and severity of ataxia [multiple system atrophy (MSA), 
Friedreich ataxia]. Concerning dementia or autism, biomarkers could be used not for 
diagnosis per se but to assess disease evolution and cerebellar involvement in 
neuropsychological-associated deficits.
While currently available radiomarkers undoubtedly help to better identify in vivo 
histological, anatomical, biochemical, and pathophysiological changes of some cerebellar 
diseases, they still lack specificity to fully and differentially characterize them. Further 
studies are thus required to evaluate the specific profile of combined radiomarkers to 
univocally identify a given cerebellar disease, to draw precise anatomoclinical correlations, 
to anticipate disease evolution and to test response to treatments. It could be also postulated 
that multivariate statistical analyses (principal component analysis, discriminant analysis, 
machine learning approaches) using a set of such biomarkers would be more powerful for 
diagnosis and prognosis than a single biomarker alone. For example, principal component 
analysis successfully discriminates two different patterns of cerebellar degeneration 
observed in SCA2 and SCA 6 [3]. This notwithstanding, such useful and promising 
“unconventional” biomarkers should from now on be incorporated to routine neuroimaging 
investigation of cerebellar diseases. The following can be recommended to apply at least and 
in complement with conventional MRI: (1) volumetric T1-weighted sequences for VBM to 
search for atrophy of the cerebellum, brainstem and striatum; (2) measurement of ADC in 
DWI and/or FA in DTI to appreciate associated tissue disorganization and cellular loss, 
(3) 1H spectroscopy to detect abnormal biochemical profile, (4) DTI and functional MRI to 
estimate structural and functional network impairment, and (5) SPECT/PET to seek for 
striatal and extra-striatal changes in MSA. More specifically, MRI patterns of regional 
cerebellar and brainstem atrophy, in some instances in combination with a characteristic 
distribution of signal or microstructural changes, are helpful diagnosis and evolution 
biomarkers of spinocerebellar, recessive (such as Joubert syndrome, Friedreich's ataxia, 
ataxia telangiectasia, autosomal recessive spastic ataxia of Charlevoix and Saguenay, 
cerebrotendineous xanthomatosis, and X- fragile tremor ataxia syndrome), and metabolic 
ataxias. Cerebellar atrophy combined with high lactate peak within the cerebellum seems 
strongly in favor of mitochondropathy-related cerebellar ataxia. Except lactate, abnormal 
peaks such as elevated N-acetyl-aspartate, galacticol or phenylalanine, may suggest specific 
metabolic ataxia. Moreover, decreased NAA/choline ratio below 5.0 might predict 
progression of X-linked adrenoleucodystrophy (evolution biomarker). Concerning nuclear 
medicine, three techniques can be applied for specific diagnoses: brain perfusion SPECT to 
detect early cerebellar blood flow abnormalities in cerebellitis, whole-body fluorodeoxy-
glucose PET (FDG-PET) in case of suspected paraneoplastic cerebellar degeneration 
syndrome and clinically occult primary malignancy, and brain FDG-PET and dopamine 
transport imaging in case of MSA. Although some cerebellar abnormalities may exist, MRI 
does not provide important data for diagnosis of immune ataxia, dementia, and autism. 
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Some cerebellar abnormalities could be linked to severity of the disease and predict impaired 
behavioral outcome, but further studies are required to validate these points.
Lastly, fetal MRI can complement ultrasound data to study white matter myelination, small 
necrotic-hemorrhagic lesion, and potential extracerebellar-associated lesions.
 Section 1: Radiological Biomarkers of Cerebellar Ataxia
Imaging modalities including computed tomography (CT), magnetic resonance imaging 
(MRI), single-proton emission computed tomography (SPECT) and positron emission 
tomography (PET) have been widely utilized in the investigation of patients with ataxia [1, 
2]. CT is typically limited to the evaluation of hemorrhage or mass lesion within the 
posterior fossa and it has virtually no role in the temporal assessment of patients with 
chronic ataxia. MRI is the imaging technique most frequently employed in the assessment of 
patients with ataxia. The high spatial and contrast resolution, in combination with 
multiplanar reformatting allows in vivo evaluation of regional atrophy, which may reveal a 
distribution pattern suggestive of a particular condition. Three fundamental patterns of 
atrophy that correspond with gross neuropathological findings are repeatedly described in 
the literature and include olivopontocerebellar atrophy, cortical cerebellar atrophy, and spinal 
atrophy. Such descriptive patterns have been substantially applied to the etiological 
classification of chronic ataxias and can help to narrow a broad differential diagnosis. T2 
signal changes in characteristic locations can provide further indicators of certain conditions 
such as multiple system atrophy, Wernicke encephalopathy, and superficial siderosis [2].
In the clinical setting, assessment of volume loss in a single patient remains largely 
subjective but with experience a reliable grading system may be achieved and can be applied 
sequentially to provide chronological appraisal. Midsagittal T1-weighted images enable the 
inspection of the brainstem and vermis while parasagittal, axial or coronal planes allow 
scrutiny of the cerebellar hemispheres and peduncles [4] Subjective assessment is limited by 
interobserver disagreement and on its dependence on observer experience. It may also lack 
sensitivity for the detection of changes early in the disease or at a subclinical phase. More 
quantitative measurements of brain atrophy may be provided with MRI-based volumetry 
whereby volumes of individual brain structures are determined via manual or automated 
segmentation [5] or by way of voxel-based morphometry (VBM), an operator-independent 
tool used to detect regionally specific differences in brain tissue composition on a voxel by 
voxel basis [6]. VBM is dependent on tissue segmentation, which ultimately requires the 
correct identification of gray and white matter and CSF partitions. In areas where gray/white 
matter differentiation is poor, voxels may be incorrectly classified. This is especially true in 
the posterior fossa and acts to reduce sensitivity [3]. Quantitative volumetric techniques 
remain largely confined to group analysis and they have been primarily employed as 
surrogate markers of disease progression in clinical research. A similar synopsis may be 
applied to non-conventional MR techniques such as diffusion, spectroscopy, magnetization 
transfer, and functional MRI. Biomarkers obtained through these sequences that offer 
quantitative assessment of microstructural integrity including apparent diffusion coefficient 
(ADC), fractional anisotropy (FA), and magnetization transfer ratio (MTR) have been 
largely evaluated in studies that have attempted to differentiate groups of patients with 
Baldarçara et al. Page 5
Cerebellum. Author manuscript; available in PMC 2016 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
different diagnoses of ataxia. While the literature is generally supportive of a role for these 
MRI techniques for cohort analysis, their value in a single patient remains unclear. The use 
of non-conventional MRI techniques as reproducible biomarkers of ataxia at the individual 
level ultimately requires the use of validated and robust techniques, which, when devoid of 
consensus multicenter data (as is currently the case), can be measured at the local 
institutional level against normal data obtained using the same imaging protocol. In these 
conditions, single-voxel 1H MR spectroscopy has been used successfully in the surveillance 
of patients with paraneoplastic cerebellar degeneration with temporal changes in N-acetyl 
aspartate, a marker of neuronal health and integrity, reportedly mirroring tumor progression/
regression [7]. A role for MR spectroscopy in monitoring the temporal changes in cerebellar 
neurometabolites in relation to dietary treatment has also been reported in patients with 
gluten ataxia [8]. Further evaluation of metabolites obtained at short echo time (such as 
glutamate) may provide indicators of cerebellar disease but currently this remains unclear.
 Section 2: Biomarkers of Cerebellar Ataxia in Nuclear Medicine
Three main types of radiotracers for SPECTor PET have been utilized with different aims to 
investigate patients suffering from acute or chronic ataxia [1].
Evaluation of regional blood flow with single-photon emission tracers, including [99mTc]-
HM-PAO, [123I]-IMP, and [99mTc]-ECD, has found two indications for diagnostic purposes 
in the single patient, namely early diagnosis of cerebellitis, that is characterized by increased 
or decreased cerebellar flow, and differential diagnosis between idiopathic late-onset 
cerebellar ataxia (pure) (ILOCA) and multi system atrophy-cerebellar type (MSA-C) with 
demonstration of more pronounced pontine hypoperfusion in the latter [1]. Regional 
perfusion was correlated with clinical features in spinocerebellar ataxia type 3(SCA3) [9], 
SCA6 and ataxia telangectasia [1]. More importantly, SPECT perfusion data were recently 
utilized as surrogate biomarkers of the efficacy of thyrotropin releasing hormone or 
immunoglobulin therapy in pilot studies of degenerative and autoimmune ataxias and 
documented increased cerebellar blood flow in line with clinical improvement in patients 
with ILOCA, SCA6, or autoantibody-positive cerebellar ataxia, but not in those with MSA 
[10–12].
Mapping brain metabolism with the positron emission tracer [18F]-FDG and head PET can 
support the diagnosis of MSA by revealing a distributed and progressive hypometabolism of 
the cerebellum, pons, basal ganglia, and frontal and parietal cerebral cortex [1, 13]. 
However, the more important clinical application of [18F]-FDG in ataxias is the whole-body 
PET examination in search of occult primary malignancy in patients with suspected 
paraneoplastic cerebellar degeneration [14]. Head [18F]-FDG-PET has also been extensively 
used for physiopathological characterization of chronic inherited or sporadic ataxias [1, 15]. 
In particular, it documented early hypometabolic areas in presymptomatic carriers of SCA2, 
SCA3, and SCA17 mutation [16–18] and showed variable correlation with severity of 
neurological deficit in cross-sectional studies [1]. In one recent study, three patients with 
cerebellar ataxia associated with antibodies against glutamic acid decarboxylase were 
examined with head [18F]-FDG before and after intravenous immunoglobulin and no further 
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decline of metabolism in the cerebellum was observed in the two patients with amelioration 
of cerebellar ataxia following immunoglobulin therapy [19].
Several single-photon or positron emission tracers are available to explore nigrostriatal 
function with SPECT or PET. The SPECT tracers include ligands of the dopamine active 
transporter (DaT) as [123I]FP-CIT, [123I]-2b-CIT, and [99mTc]-TRODAT-1 and of the 
postsynaptic D2 receptors as [123I]-IBZM. SPECT with DaT tracers, comprehensively called 
DaT-Imaging, can support the diagnosis of MSA by demonstrating decreased striatal uptake, 
which is typically combined with decreased striatal D2 receptors [1]. They were also 
extensively utilized for physiopathological characterization of other chronic inherited or 
sporadic ataxias [1]. PET tracers of nigrostriatal function including [18F]-FDopa and ligands 
of striatal dopamine transporter as [11C]d-MP and of D2 receptors as [11C]-raclopride have 
been used for the same purposes with similar results to those obtained with SPECT tracers 
[1]. Notably, nigrostriatal dysfunction was observed in presymptomatic carriers of the 
SCA2, SCA3, SCA6, and SCA17 genes [1, 18, 20, 21].
A last group of positron emission tracers including ligands of GABA/benzodiazepine 
receptors as [11C]-FMZ and markers of the acetylcholinesterase activity as [11C]-PMP was 
used for physiopathological characterization of chronic inherited or sporadic ataxias [1, 19].
Overall, in patients with ataxias, despite the relatively large number of nuclear medicine 
studies and the valuable contribution that SPECT and PET can provide for diagnosis in the 
single patient and to understand the physiopathology of ataxia disorders, there is relative 
paucity of data about the capability of SPECT and PET to track progression of disease or to 
serve as surrogate markers for new treatments [1, 10–12, 19]. Noteworthy and of potential 
major impact for these crucial applications is incorporation in a recent study of PET with a 
striatal D2 receptor marker, namely [11C]-raclopride, in the assessment of an animal model 
of SCA17 [22].
 Section 3: Radiological Biomarkers of Fetal Cerebellar Developmental 
Alterations
State of the art ultrasound (US), performed by expert neurosonographers and by using 3D-
reformatted technique, is able to detect the majority of fetal cerebellar anomalies [23], such 
as hypoplasia, rhombencephalosynapsis, cystic malformations as Dandy-Walker, and large 
necrotic-hemorrhagic lesions. However, in some abnormal conditions, fetal magnetic 
resonance (MR) imaging may add additional and valuable information [24].
When fetal MR scanning begins to be performed in clinical setting (usually around the 18th–
20th week of gestation), the general final shape of the cerebellum is already recognizable on 
multiplanar ultrafast T2-weighted (3–5 mm thick) sections: the vermis in its final position, 
almost adhering to the fourth ventricle floor on midsagittal section; the primary fissure 
visible in most cases; middle cerebellar peduncles clearly visible, especially on axial 
sections. It is important to assess the relationship between cerebellar vermis and the pontine 
bulging, the level of tentorium occipital insertion (normally at nuchal muscles insertion 
level), and the dimension of the cisterna magna [25]. Linear biometry of the vermis and 
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cerebellar hemispheres is usually assessed [26]. Later during the pregnancy, the volume of 
cerebellum accelerates its growth [27]; close to the 30th week of gestation, additional 
vermian fissures are often recognizable on midsagittal image, and the hypointense signal of 
myelination is noticeable in the pontine tegmentum.
 Clastic Lesions
MR imaging may highlight smaller necrotic-hemorrhagic hemispheric lesions better than 
US. They are mostly of unknown etiology, often unilateral, located in the caudal part of 
cerebellar hemispheres, involving or not the vermis; such lesions usually appear as T2-
hypointense foci, with some superficial filaments or micro-cysts (probably due to arachnoid 
reaction), and sometimes with hyperintense T1 spots. They usually tend to evolve toward 
cerebellar hemiatrophy [28], with areas of irregularly invaginated and oriented folia. When 
hemosiderin deposits are no longer visible in postnatal MR imaging, it may be difficult to 
differentiate such lesions from those of genetic etiology.
 Cerebellum–Pontine Hypoplasia
3D-US is usually sufficient to highlight significant cerebellum and pons volume reduction in 
these non clastic anomalies; however, MR imaging may help to exclude associated 
intracranial pathologies and to prove that the entire cerebellum is usually decreased in size.
 Complex Malformations
The diagnosis of some complex malformations of cerebellum and brainstem, such as molar 
tooth group, incomplete non classical rhombencephalosynapsis, brainstem kinking in 
muscle-eye brain diseases, pontine-tegmental cap or still unclassified and emerging ones, 
such as bilateral foliation orientation derangement, may benefit from MR imaging, 
especially before the 24th week of gestation; the features of such malformations are usually 
similar to the ones of postnatal MR imaging, but, because of the limited spatial resolution, a 
definite diagnosis may still be very difficult in utero; in these cases, the use of higher-
resolution (2 mm thick) true-FISP or BALANCE sections may be advised.
 Upward Rotation of Cerebellar Vermis
This is one of the still most challenging conditions in prenatal counselling, albeit one the 
most frequent. Not totally definable and still unclear vermian entities, such as “caudal 
hypoplasia”, “incomplete rotation”, “Dandy-Walker variant”, challenge the reproducibility 
of scientific reports on this regard and the possibility of a reliable prognosis. MR imaging 
may complement US in order to better deal with such conditions, especially by excluding 
the possibility of other intracranial anomalies [29]. When vermian upward rotation 
(cerebellar-pontine angle above 8–10°) is really isolated (normal karyotype, no other 
intracranial or body anomalies at prenatal imaging, normal latero-lateral cerebellar diameter, 
and normal brainstem appearance), the probability of a good prognosis is higher than 80 %, 
with many cases undergoing even angle normalization [30]; however, fetal MR imaging is 
currently still unable to identify that minority of cases, which will experience significant 
behavioural and neurological anomalies.
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In summary, main prenatal MR imaging markers, which help to differentiate between 
clastic- and genetic-based cerebellar anomalies are: (1) in favour of a clastic etiology: 
presence of unilateral anomaly with focal hemispheric surface distortion (i.e., paravermian 
unilateral cleft), presence of hemosiderine deposits, associated clastic signs in supratentorial 
compartment (i.e., cerebral hemorrhages or parenchymal edema, T1-weighted hyperintense 
foci of cortical necrosis, lateral ventricles septa and sinechiae), cysts within the tip of 
temporal lobes (as in CMV infection), venous sinuses engorgement, (2) in favor of a genetic 
etiology: presence of very symmetric bilateral dysmorphism (i.e., folia malorientation), 
vermian hypoplasia and upward rotation with clearly enlarged posterior fossa, associated 
brainstem anomalies (i.e., midline cleft, megatectum, pontine cap), associated skull 
anomalies (i.e., occipital encephalocele), associated suprantentorial anomalies (i.e., short 
corpus callosum, hippocampal malrotation, reduced opercularization, band heterotopias), 
associated head-neck anomalies (i.e., palatine schisis, optic nerve head coloboma).
 Section 4: Structural and Functional Neuroimaging in Autosomal 
Dominant Spinocerebellar Ataxias
Autosomal dominant spinocerebellar ataxias (SCAs) are a heterogeneous group of 
progressive neurodegenerative disorders, caused by diverse genetic mutation types and 
complex pathogenesis, and clinically mainly characterized by cerebellar ataxia, including 
unsteady gait, clumsiness, and dysarthria. The cerebellar syndrome is often associated with 
other neurological signs such as pyramidal or extrapyramidal symptoms, ophthalmoplegia, 
and cognitive impairment. Onset is generally during the third or fourth decade of life, but 
can also occur in childhood or elderly. Atrophy of the cerebellum and brainstem are most 
often the prominent imaging features, but other structures can be also affected, leading to a 
wide range of phenotypes. Longitudinal studies indicate further that there might also be a 
disease-related, genotype-specific staging progression of neurodegeneration patterns. 
Correlations between phenotype and genotype in the polyglutamine expansion have shown 
that differences in repeat size may contribute to age at onset, disease progression, severity, 
and clinically different phenotypes between patients. Functional imaging studies have 
further enhanced a better understanding of pathological findings and their association to 
clinical features in these disorders. As most neuroimaging data are available for the more 
common subtypes SCA1, SCA2, SCA3, SCA6, SCA7, and SCA17, they are described in 
more detail in the following. Major magnetic resonance imaging (MRI) characteristics are 
schematically presented in Fig. 1. An overview for all SCAs is given in Table 1.
Structural neuroimaging in SCA1 revealed atrophy predominantly in the brainstem, 
cerebellum, and basal ganglia [31, 32]. Even in preclinical SCA1 mutation carriers 
compared to non-carriers gray matter loss in the medulla oblongata and pons was detectable 
[33]. Compared to other SCAs, the typical olivo-ponto-cerebellar atrophy in SCA1 was 
described as similar but not as severe as in SCA2 [31, 34] and more prominent than in SCA3 
with respect to the cerebellar hemispheres [32]. A longitudinal MRI study, combining 
quantitative volumetry and voxel-based morphometry (VBM), revealed that pontine volume 
was the most sensitive measure of disease in SCA1, which was superior to the most sensitive 
clinical measure, the Scale for the Assessment and Rating of Ataxia [35]. There was further 
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a mild correlation between CAG repeat length and volume loss in the bilateral cerebellum 
and the pons in SCA1. The ponto-cerebellar brunt in SCA1 is further supported by 
alterations in white matter, as assessed with VBM and diffusion tensor imaging (DTI) 
including mean diffusivity (MD) and Tract-based spatial statistics (TBSS) [35, 36]. 
Structural and functional connectivity analyses using functional MRI and DTI revealed a 
loss of intrinsic organization of cerebellar networks, which correlated with disease severity 
and duration in this disconnection syndrome [37].
MRI in SCA2 revealed marked atrophy of the cerebellum, pons, medulla oblongata, and 
spinal cord, and also showed an involvement of the parietal cortex and thalamus [38, 39]. In 
preclinical stages, volumetric analyses showed reduced normalized brainstem volumes of 
SCA2 mutation carriers compared with non-carriers [33]. Using clinical and 
neuropsychological assessments impaired coordination was linked to atrophy in the anterior 
cerebellum and executive impairment to atrophy in the posterior cerebellum [38], and ponto-
cerebellar volume loss was associated with decreased functional staging scores.
Patterns of ponto-cerebellar atrophy in the worldwide most common SCA3 have been 
reported in several neuroimaging studies, which is similar but less severe to SCA1, SCA2 
(regarding pons), or SCA6 (regarding cerebellum) [31, 32, 34]. MRI revealed further 
atrophy in the superior cerebellar peduncles, frontal and temporal lobes, as well as 
diminished transverse diameter of the pallidum. The involvement of the basal ganglia in 
SCA3 has also been described in previous volumetric measurements [31]. Quantitative 
three-dimensional volumetry and VBM demonstrated severe atrophy in total brainstem, 
pons, medulla, total cerebellum, cerebellar hemispheres and cerebellar vermis, putamen and 
caudate nucleus in SCA3 [32]. The role of putaminal volume loss in SCA3 was underlined 
further by a 2-year follow-up MRI study revealing most pronounced changes in the putamen 
[33].
Neuroimaging studies in SCA6 reported moderate to severe atrophy of the vermis, mild 
atrophy of the cerebellar hemispheres, but no atrophy of the middle cerebellar peduncles, 
pons or other structures of the posterior fossa [39, 40]. Notably, mild, diffuse atrophy of 
cortical areas has been described in some SCA6 patients [35]. A cross-sectional volumetric 
and VBM study showed atrophy in SCA6 predominantly in the cerebellum but also in total 
brainstem and pons [32], and longitudinally, the most sensitive area to volume loss was the 
caudate [35]. Longitudinal VBM showed the greatest gray matter loss in the cerebellum, 
thalamus, putamen, and pallidum [35].
MRI studies in SCA7 have shown diminished volumes mainly in the cerebellum and pons, 
while T2 images indicate hyperintensities in transverse fibers at the pons. Overall, the most 
consistent finding in MRI studies is pontine atrophy. Compared to other SCAs, atrophy in 
the pons in SCA7 seems as severe as in SCA2, and more pronounced than in SCA3 and 
SCA6. A recent VBM and TBSS study demonstrated bilateral gray matter volume 
reductions in the cerebellar cortex and also in pre- and postcentral gyri, inferior and medial 
frontal cortex, inferior parietal cortex, parahippocampal gyrus, and occipital cortex [41]. 
This study also showed diffuse reductions in fractional anisotropy in the cerebellar white 
matter, brainstem, cerebellar and cerebral peduncles, midbrain, anterior and posterior 
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internal capsule, external/extreme capsule, corpus callosum, corona radiata, optical 
radiations, and the occipital, temporal and frontal lobe white matter. These results confirm 
previous evidence of widespread damage beyond the cerebellum and the pons in SCA7.
MRI studies in SCA17 have revealed severe structural alterations in the cerebellum [42, 43]. 
It has been demonstrated that the extent of cerebellar neurodegeneration correlates with a 
variety of clinical motor features such as ataxia and extrapyramidal signs, and also with a 
broad spectrum of neuropsychiatric symptoms and negatively correlated with the number of 
CAG repeats [44]. The motor-related neurodegeneration has been shown to be progressive in 
a longitudinal study [45]. Recently, a task-based meta-analytic connectivity modeling and 
task-free resting state functional connectivity analysis showed differential functional 
connectivity of anterior and/versus posterior cerebellar atrophy as revealed by VBM analysis 
in SCA17 [46]. This study highlights the manifold connections and anterior-posterior 
dichotomy of the human cerebellum, providing additional valuable information about 
disrupted cerebellar–cerebral connections potentially underlying motor and neuropsychiatric 
deficits in SCA17.
 Section 5: Imaging in Immune-Mediated Ataxias
 Introduction
This section will cover immune-mediated ataxias including gluten ataxia, anti-glutamic acid 
decarboxylase (anti-GAD) associated ataxia, paraneoplastic cerebellar degeneration, primary 
autoimmune cerebellar ataxia and post infectious cerebellitis.
 Gluten Ataxia
The first description of the imaging findings in patients with gluten ataxia described 
cerebellar atrophy in 6 out of 28 patients [47]. Subsequently Wilkinson et al. [48] used 
single voxel 1H MR spectroscopy of the right cerebellar hemisphere to investigate the 
presence of abnormal underlying cerebellar neurochemistry in patients with gluten ataxia 
(GA). The group demonstrated significant reduction in mean NAA concentration at short 
echo time and in NAA/Cho ratios at intermediate echo time in subjects compared with 
healthy controls. The authors concluded that cerebellar neuronal physiology is abnormal in 
patients with GA even in the absence of cerebellar structural deficit and that MR 
spectroscopy may prove a useful tool for monitoring disease. However, more recent work 
has indicated that the MR spectroscopy was only statistically abnormal compared to controls 
from the vermis which also reflects the pattern of atrophy seen, which affects the vermis 
earlier and more severely than the hemispheres [48, 49]. There is no published longitudinal 
evidence of the use of MR spectroscopy for follow up of patients with GA. In addition to the 
cerebellar findings, more widespread imaging abnormalities have been demonstrated 
amongst a population of patients presenting with celiac disease who report vague 
neurological symptoms [50]. Gluten ataxia appears to be associated in some individuals with 
accelerated white matter abnormalities compared to age-matched controls, suggesting some 
overlap in gluten-related neurological disease. The mechanism has not yet been elucidated.
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 Anti-glutamic Acid Decarboxylase Antibody Associated Ataxia
Anti-GAD antibodies have been described in autoimmune diseases such as types I diabetes 
and multiple endocrine syndromes, and have also been found in a Stiff person syndrome and 
in some sporadic ataxias. It remains unclear if these antibodies are pathogenic or just a 
marker of multiple autoimmunity. Honnorat et al. [51] described a series of 14 patients with 
a cerebellar syndrome with anti-GAD antibodies, 11 of whom had late-onset insulin-
dependent diabetes. The group reported that 7 of the 14 had normal MR imaging and the 
others pure “cerebellar atrophy”, none had brainstem atrophy. In a series of six patients, 
Nanri et al. [52] recently described cerebellar cortical atrophy using voxel-based 
morphometry in all six patients with low titre GAD-antibody positive ataxia. The group also 
undertook SPECT imaging and reported reduced perfusion in one patient, other patients 
were not reported. There are no longitudinal imaging reports in the literature to assess the 
rate of cerebellar atrophy, correlations of clinical features to imaging biomarkers nor are 
there even specific reports of the patterns beyond the descriptions above. This perhaps 
reflects the rarity of the condition or it may be that the main imaging biomarker assessed 
(atrophy) is not clinically useful.
 Paraneoplastic Cerebellar Degeneration
Conventional, structural MRI findings are frequently normal early in the course of 
paraneoplastic cerebellar degeneration (PCD) but imaging can show cerebellar atrophy later 
in the course of the disease. Atrophy in some cases may become apparent rapidly, with 
reports of atrophy arising after only 1 month of symptoms [53]. De Andres [54] has reported 
similar florid imaging changes demonstrating T2 signal changes and cerebellar tissue 
swelling in keeping with underlying edema just 2 months after onset of clinical symptoms. 
The cerebellum subsequently became atrophic after 2 months. Choi et al. [55] reported 
hyperactivity of the cerebellum on brain with F-FDG-PET suggesting a very active process. 
However, F-FDG-PET may also show hypometabolism of the cerebellum [56]. Early and 
profound reductions of NAA have also been reported on MR spectroscopy [55], which 
would be expected from a very active and rapid progression [7]. The same report suggested 
that MR spectroscopy may be a potentially useful biomarker, by showing improvement in 
NAA/Cr ratio following chemotherapy of the cancer but also alerting the clinician for repeat 
PET imaging after a fall in NAA/Cr ratio. Tumor recurrence was subsequently confirmed. If 
there are no clinical features to suggest a primary tumor but PCD is still suspected, PET 
imaging should be used as per standard investigation for an unknown primary cancer [57].
 Primary Autoimmune Cerebellar Ataxia
Primary autoimmune cerebellar ataxia (PACA) is a term that implies an autoimmune cause 
for a sporadic cerebellar ataxia that is underpinned by an appropriate HLA type such as type 
DQ2 or DQ8, possibly a history of other autoimmune conditions affecting the patient or 
their first degree relatives. There is no specific biomarker as yet, although cerebellar 
antibodies were found with higher frequency compared to the normal population and those 
patients with genetic ataxia (47 %, 3 % and 5 %, respectively) [58]. While atrophy of the 
cerebellum has been described in PACA, currently, there is no evidence for any specific 
imaging feature [59].
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 Post Infectious Cerebellitis
Post infectious cerebellitis is normally a monophasic illness with ataxia presenting following 
an infection which may be subclinical. Imaging plays a modest role in diagnosis; T2 signal 
change of the cerebellum is widely documented [60, 61] but structural MRI findings maybe 
normal if patients are imaged early in the course of the illness [62, 63]. While SPECT 
perfusion has been reported as a potential diagnostic biomarker in the course of the illness, 
reports vary with both increased and decreased perfusion demonstrated alongside normal 
MR appearances of the cerebellum [62, 63]. The pattern of cerebellar involvement is 
variable, though with the Purkinje cell a frequent immunological target in immune-mediated 
ataxia of which nature there is often a predominant cerebellar cortical volume as tends to be 
found in other immune ataxias [59]. Most patients make a full recovery with no residual 
imaging abnormalities. In a minority, there is subsequent evidence of cerebellar atrophy, 
sometimes with evidence of progression. This latter group, however, may fall into the 
category of primary autoimmune cerebellar ataxia.
 Section 6: Radiological Biomarkers of Cerebellar Alteration in Dementia
The cerebellum has traditionally been seen as a brain area limited to the coordination of 
voluntary movement, gait, posture, speech, and motor functions. However, there are 
increasing evidence proving that the cerebellum is implicated in processes associated with 
the control of cognition, behavior, and psychiatric illness [64, 65]. Moreover, the fact that 
the cerebellum is reciprocally connected to a broad range of limbic structures including the 
amygdala and hippocampus, as well as the cerebral cortex including the prefrontal areas, 
provides a strong neuroanatomical argument in favor of cerebellar involvement in cognition 
regulation [66].
Functional neuroimaging studies show that the cerebellum is involved in multiple cognitive 
functions, including working memory and attention [67–69]. Damage to the cerebellum, 
particularly the posterior lobes and vermis, is consistently associated with cognitive deficits 
[69–72]. In young, healthy adults, some studies have found that cerebellar size is associated 
with individual differences in cognitive ability [69, 73]. The cerebellum is relatively 
vulnerable to atrophy occurring with aging and cognitive domains known to involve the 
cerebellum, for example, working memory, are vulnerable to decline with aging [67, 74]. In 
this context, some researchers have showed an interest in supratentorial atrophy [68, 75–77]. 
Although population-based studies have widely investigated structural properties of the 
cerebrum, the cerebellum has received little attention [78].
Dementias constitute a heterogeneous group of diseases that share cognitive impairment of 
organic etiology. Although several causes and pathophysiological mechanisms underlie the 
clinical presentation of different types of dementia, neuroimaging studies have confirmed 
some common findings such as atrophy of certain brain structures or even global brain 
atrophy and progressive impairment of different cognitive domains [65]. In Alzheimer's 
Disease (AD), for example, temporal lobe volume reduction is observed even at early stages 
of the disease, and hippocampal reduction can be observed before the first symptoms [65].
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Cerebellar changes can occur in several types of dementia [65, 79–82]. Generally, these 
findings are organized in neuroimaging secondarily, on the other hand, some cerebellar 
diseases may also present with dementia. Regardless of place of primary amendment, each 
disease shows morphological alterations of the cerebellum in a particular way. Besides, in 
neuroimaging studies, the greatest difficulty in assessing cerebellar changes is that this 
structure is generally used as a control, in other words, it is considered as a structure free of 
the condition to be compared to cerebrum alterations. Therefore, the study of cerebellar 
changes in dementia is a new perspective in understanding the neurodegenerative diseases 
and enables a new way of understanding its pathophysiology, symptoms, and treatment, and 
prognosis mainly. Additionally, since the cerebellum participates in the regulation of motor 
activity, working memory, attention, and executive functions, the changes suffered by it may 
be related to loss of functionality, one of the factors related to the prognosis of dementia.
In previous studies about cerebellar abnormalities in different types of dementia, the most 
relevant finding is diaschisis, that is the cerebellar hypoperfusion or hypometabolism related 
to the atrophy of superior structures and is commonly observed at late stages of disease [83–
85]. The main hypothesis suggesting the implication of the cerebellum in dementia invokes a 
possible role for diaschisis [65, 75–77], however, it was demonstrated that cerebellar volume 
reductions can be observed even at early stages of the disease [65]. Moreover, there are 
reports that secondarily affected regions could present mild atrophy and no histopathological 
changes [76]. Possible reasons for cerebellar volume reductions in dementia include vascular 
factors, toxins (e.g., alcoholic dementia) [65, 75, 76, 80], and normal aging [75].
In structural MRI in AD, cerebellar volume is reduced [65, 77, 83, 86] and shows 
microstructural changes [84]. There is gray matter density reduction in AD compared to 
healthy controls as an independent variable [84]. Cerebellar lobes volume, posterior 
cerebellar lobes, and vermal volume reduction are the main findings in AD patients when 
compared to healthy controls, and that this atrophy is associated with poorer cognitive 
performance in AD [77]. The volume reduction is an independent variable; besides, 
reduction in superior structures are present [72]. The volume reduction is more evident in the 
late stages of disease. In addition, right cerebellar hemisphere and vermis volumes have a 
negative correlation with the functional activities [65].
In functional and molecular research, usually, the cerebellum is often used as a control 
structure, since this structure is free of neurofibrillary and Ś-amyloid pathology (except in 
very late states). A significant reduction of blood flow in cerebellum was observed in 
patients with AD compared to healthy controls [85]. Other groups observed that the glucose 
metabolism in the cerebellum was significantly lower in patients with AD comparing to 
healthy controls and this reduction correlated with MMSE [87]. Using functional MRI 
(fMRI), Vidoni and colleagues [88] observed that individuals without dementia exhibited 
greater activation in accessory motor regions supplementary motor area and cerebellum 
compared to those with AD.
In other types of dementia, cerebellum morphology is not assessed frequently and few data 
are available. In vascular dementia, cerebellar changes are diverse and brain atrophy can 
occur directly by vascular lesion in the cerebellum or secondary to cerebrum atrophy [89]. 
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Studies have already found the fact that after stroke, the cerebellum suffered from reduction 
in metabolism and blood flow in the cerebellar hemisphere contralateral to a destructive 
cerebral lesion [79, 90]. But there is a particular change in subcortical vascular dementia that 
present with cerebellar volume reduction, and the number of subcortical lacunes correlates 
with cerebellar atrophy [91].
There is reduction in the gray matter of the cerebellum in frontotemporal dementia, and 
there is hypometabolism in the cerebellum together with hypometabolism in the prefrontal 
cortex, thalamus, parietal-occipital white matter, lenticular nucleus of the basal ganglia, and 
pons [80, 91]. After a working memory task, frontal regions in patients with FTD showed 
less linear activation, but the cerebellum shows a stronger increasing response in FTD [78], 
suggesting a compensatory mechanism.
In Parkinson disease (PD) there is gray matter volume decrease in the right quadrangular 
lobe and declive of the cerebellum in subjects with tremor compared with those without. 
Increased activation of the cerebellum in PD appears not only during motor execution, but 
also during the motor learning process [81]. But the patients with PD in a gait-induced task 
have hypoactivation in the left medial frontal area, right precuneus and left anterior lobe of 
the cerebellar hemisphere, but hyperactivity in the left temporal cortex, right insula, left 
cingulate cortex, and cerebellar vermis [90].
In Huntington's disease (HD), the anger recognition deficit was correlated with atrophy of 
selected hemispheric and vermal regions of the cerebellum in addition to the common 
findings of basal ganglia including the caudate nuclei, putamen, and globus pallidus [82]. 
Furthermore, cerebellar volume reductions of the HD patients were associated with longer 
disease duration and greater functional impairment [82].
Fahr's disease (FD) is characterized by sporadic or familiar idiopathic calcification of the 
basal ganglia, dentate nuclei of the cerebellum, and centrum semiovale, mainly presenting 
with movement disorder, dementia, and behavioral abnormalities [92, 93]. In Fahr's 
syndrome brain CT, the most frequent site of calcification is in basal ganglia, and MRI 
shows atrophy in parietotemporal regions. But deposits may be present in the cerebellum 
[92, 93].
Finally, Creutzfeldt-Jakob Disease (CJD), that is the most common prion disease, 
characterized by a rapidly progressive multifocal neurological dysfunction, myoclonic jerks, 
and a terminal state of global severe cognitive impairment [94]. Magnetic resonance imaging 
of the brain may have an important role in the diagnosis of disease [95]. Typical MRI 
findings in CJD patients consist of hyperintense signals in the cortical ribbon, basal ganglia, 
and the thalamus on diffusion-weighted images (DWI) and fluid-attenuated inversion 
recovery (FLAIR). Despite the intense neuropathological involvement of the cerebellum in 
CJD [96] and presence of cerebellar symptoms [97, 98], it is commonly negative in imaging 
studies [99, 100]. More recently, Cohen et al. found that apparent diffusion coefficient values 
are elevated in cerebellar structures [94]. There is increased cerebrospinal fluid volume in 
the posterior cranial fossa suggesting cerebellar atrophy. The author proposed this atrophy as 
a radiological hallmark of cerebellar pathology in CJD [94]. In Sporadic Creutzfeldt-Jakob 
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disease (sCJD), there is a hypometabolism in the cerebellum measured by SPECT or PET 
and the presence of hyperintensities on MRI. In familiar form, there is reduction of 
metabolism as in sCJD [79].
Another type of prion diseases could present without abnormalities, atrophy, or another 
small findings. For example, the Gerstmann–Sträussler–Scheinker syndrome (GSS) is 
characterized by slowly progressive cerebellar ataxia accompanied by cognitive impairment, 
spastic paraparesis, and extrapyramidal signs. In this disease, there is decrease in the 
NAA/Cr ratio in the frontal lobe, cerebellum, and putamen even in the absence of other 
abnormal imaging results [100].
Based on preliminary findings, there is evidence that the cerebellum could be impaired in 
dementia. Although cerebellar changes accompany similar changes in the cerebrum, they 
cannot be considered as an isolated factor only. We have hypothesized two possible ways in 
which cerebellar volume and function may change: (1) cerebellar impairment could be 
secondary to cerebral volume reduction, or (2) cerebellar impairment could be evident prior 
to cerebral impairment and could be related to other factors. These hypotheses suggest that 
cerebellar volume reductions can be considered as a risk factor for later dementia onset. As 
the cerebellum participates in coordination, gait, and in some cognitive functions (as 
executive), its impairment could be related to the outcome and mortality rates in dementia 
[101]. Therefore, a better understanding of the role of the cerebellum in dementia could offer 
new possibilities for prevention and rehabilitation.
 Section 7: Markers of Cerebellar Alteration in Autism Spectrum Disorder
 Markers of Cerebellar Alteration in Autism Spectrum Disorder
Autism spectrum disorder (ASD) is an early-developing disorder marked by impairments in 
social communication and restricted and repetitive interests [102]. The cerebellum of 
individuals with ASD often manifest marked anomalies. Recent conceptions of the 
cerebellum link this structure, via its robust afferent and efferent connections, to nearly every 
major neural system—including prefrontal, posterior parietal, temporal, and limbic 
structures—and to a broad suite of functions [103] including many known to be abnormal in 
ASD. Early cerebellar abnormalities in ASD could contribute to the altered developmental 
trajectories and heterogeneity evident in this disorder.
 Cellular and Molecular Findings
Postmortem studies in patients with ASD have consistently documented reduced Purkinje 
cell (PC) density in the hemispheres and vermis [104]. This reduction may be greatest in 
Crus I and II [103], regions of the so-called “cognitive cerebellum” with linkages to non-
motor cortical association regions. Dysregulation of chemicals involved in cellular migration 
(Reelin) and apoptosis (Bcl-2) has been found in the cerebellum of individuals with ASD 
[105], providing one potential explanation for PC reductions.
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 Genetics of the Cerebellum in ASD
Work has implicated engrailed 1 and 2 (EN1 and EN2) as potential candidates for cerebellar 
pathology: Human EN2 maps to a region of chromosome 7 that has been linked to ASD 
[106], and EN2 mouse mutants display relevant ASD-like features such as PC reductions 
[107] and reduced exploratory behaviors [108]. Another genetic link may be MET 
(transmembranar receptor tyrosine kinase of the hepatocyte growth factor/scatter factor), 
which is implicated in neuronal development in the cerebellum [109], and has been 
implicated in genetic analyses of 7q in autism families [110].
Gene by environmental interaction could also result in PC loss due to prenatal neuro-
inflammatory reactions (i.e., neuroglial activation) [111]. In mouse models, prenatal viral 
infections result in dysregulation of myelin-associated genes in the cerebellum, which 
appears to lead to alterations in cerebellar white matter [112, 113].
 Volumetric Findings
Courchesne and colleagues [114] have proposed that within the cerebellum, there may be in 
ASD early overall cerebellar enlargement with decreased or arrested growth during 
childhood. In contrast to the development of the cerebellar hemispheres, the superior 
posterior vermis (vermal lobules VI–VII) may be significantly smaller in a subset of autistic 
patients (for meta-analysis [115]). Cerebellar vermis has connectivity with limbic and 
paralimbic regions, and activity in vermis VI–VII is associated with emotional processing in 
nonclinical samples [104]. Volumetric data on the other vermal lobules (I–V, VIII–X) are, 
however, inconsistent, and vermal growth trajectory in ASD is unclear. Trajectories of 
different vermal lobules may vary, with I–V and VI–VII, but not VIII–X, “catching up” by 
adolescence. As yet undetermined is the implication of altered and different trajectories 
within specific cerebellar lobules.
 Cerebello-Cortical Connectivity
Contemporary theories of cerebellar function suggest that cerebellar neuronal operations are 
uniform, but that their outcomes differ based on highly specific patterns of cerebello-cortical 
connectivity. Thus, fully understanding the nature and downstream implications of cerebellar 
disruptions depends on robustly characterizing cerebello-cortical connectivity in ASD as 
well as disruptions to the cerebellum in isolation. A few investigations in this domain 
suggest atypical functional [116] and anatomical connectivity [117]; however, this area is 
ripe for further research.
 Cerebellum and Behavior in Autism
In ASD, cerebellum volume and white matter integrity have been shown to be associated 
with performance IQ [118], repetitive behaviors [119, 120], social behaviors [116], and 
symptom discrepancies [121]. However, not all reports find behavioral relations [122]. 
Resolving the inconsistency across reports, in terms of whether these relations do exist and 
in which domains, may necessitate greater attention to how these complex behaviors might 
be linked to topographically varying patterns of cerebellar connectivity, as well as how these 
relations might covary with methodological considerations and variability in sample 
characterization.
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 Cerebellar Treatment Targets in ASD?
Although the cerebellum has been identified as a potential region of interest for ASD, it has 
received little attention as a potential therapeutic target [103]. One potential pharmacological 
target is cerebellar GABAergic dysfunction, which has been repeatedly demonstrated in 
ASD [112]. The GABA B receptor agonist, arbaclofen, has been reported to be helpful in 
preliminary trials for irritability and social withdrawal in autism, and is moving forward in 
clinical trials [123]. Another avenue may be calcium channelopathies. Increased cerebellar 
activity of the enzymes Na(+)/K(+)-ATPase and Ca(2+)/Mg(2+)-ATPase in ASD could 
represent a compensatory response to increased intracellular calcium concentration, 
representing a potential drug development target [124].
 Section 8: Structural and Functional Neuroimaging in Autosomal 
Recessive and X-Linked Ataxias
 Autosomal Recessive Ataxias
Autosomal recessive ataxias represent a very heterogenous and relatively numerous group of 
diseases which can be variably classified according to clinical features, including age of 
onset, disease progression rate and associated signs, neurophysiology findings or underlying 
genetic abnormality (Table 2) [125]. Neurophysiological findings and several characteristic 
or pathognomonic laboratory findings can help in the differential diagnosis of autosomal 
recessive ataxias, whereas the most common MRI finding, namely cerebellar atrophy, is 
nonspecific [125]. However, taking into consideration the pattern of inheritance which 
implies in some cases a less evident familiar transmission of the disease as compared to 
autosomal dominant ataxias, it is important to be aware that some autosomal recessive 
ataxias show typical MR imaging features which can serve as crucial diagnostic biomarkers 
in the single patient (Fig. 2 and Table 2). These include: “molar tooth” sign in Joubert 
syndrome and related disorders (ciliopathies) [126, 127]; a pattern of spinal atrophy 
combined with symmetric high signal in the lateral and posterior columns of the cervical 
spinal cord in Friedreich ataxia [1]; cortical cerebellar atrophy combined with foci of 
hypointensity on T2*-weighted gradient echo images corresponding to capillary 
telangectasias in ataxia telangectasia [128]; atrophy of the superior cerebellar vermis, a 
bulky pons exhibiting T2-hypointense stripes corresponding to the corticospinal tracts and 
medial leminsci, thinning of the corpus callosum and a rim of T2-hyperintensity around the 
thalami in autosomal recessive spastic ataxia of Charlevoix-Saguenay [129]; symmetric high 
signal in the hilum of the dentate cerebellar nuclei on T2-weighted images in 
cerebrotendineous xanthomatosis (CTX) [130].
Quantitative MR and nuclear medicine techniques have been successfully used for 
physiopathological characterization of some autosomal recessive ataxias, namely 
Friedreich's ataxia (FRDA), ataxia with oculomotor apraxia type 2 (AOA2), CTX and 
Niemann–Pick type C (NPC) disease.
FRDA is the most common autosomal recessive ataxia which is now readily diagnosed by 
demonstration of expanded GAA trinucleotide repeat in both the alleles of a gene encoding a 
mitochondrial protein named “frataxin”. Conventional MR imaging shows atrophy of the 
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cervical spinal cord and medulla and symmetric T2 high signal in the lateral and posterior 
WM columns of the spinal cord [1]. More importantly, some quantitative MR measures were 
reported to be correlated with severity of clinical impairment. These include reduced 
thickness and increased proton diffusion of the cerebellar WM and superior cerebellar 
peduncles [131–134]. In addition, a measure of the integrity of the superior cerebellar 
peduncles, namely magnetization transfer ratio, correlated with the number of GAA triplets 
in the larger repeat size in a recent study [135]. FDG-PET demonstrates a distinctive diffuse 
pattern of increased glucose metabolism in the brain of FRDA patients with mild to 
moderate clinical impairment [136]. Conversely, in patients with more severe deficit, a 
normal pattern or decrease of glucose metabolism in the cerebral cortex, the cerebellum, and 
the brainstem, is observed [136].
MRI in AOA2 shows a nonspecific cortical cerebellar atrophy pattern associated with stroke-
like cerebral lesions, whereas proton MR spectroscopy shows lower N-acetyl-aspartate 
(NAA) consistent with neuronal loss/dysfunction in the cerebellar vermis and hemispheres, 
increased myo-inositol indicative of gliosis in the pons and vermis and decreased glutamate 
in the vermis [137]. The cerebellar NAA concentration correlates with severity of clinical 
cerebellar deficit.
In CTX, a decrease of NAA combined with increase of lactate was observed in the 
supracallosal brain, which correlated with clinical disability, and in the deep cerebellar WM 
[138].
In NPC patients, thinning of the corpus callosum is correlated with duration of the disease 
and measures of clinical severity [139]. Moreover, a recent morphometry study [140] 
indicated that NPC patients shows a significant reduction in both gray and white matter 
cerebellar volumes and that volume loss is correlated with saccadic gain and ataxia 
measures, but not with symptom duration or severity. In a proton spectroscopic imaging 
study of NPC disease, NAA/creatine was significantly decreased in the frontal and parietal 
cortices, centrum semiovale and caudate nucleus, whereas choline/creatine was significantly 
increased in the frontal cortex and centrum semiovale [141]. Significant correlations were 
found between clinical staging scale scores and these proton spectroscopy abnormalities.
Although overall, the above findings suggest a role of MR or nuclear medicine measures as 
progression and surrogate biomarkers of recessive ataxias, to date, these potentials of 
neuroimaging techniques have not been proven in longitudinal studies.
 X-Linked Ataxias
The most common form of X-linked ataxia is the Fragile X-associated tremor ataxia 
syndrome (FXTAS) [142, 143]. In 57 % of FXTAS cases, there is familial history of mental 
retardation affecting a boy due to full (in excess of 200) expansion of a CGG triplet in the 
fragile X mental retardation 1 gene [143]. Accordingly, FXTAS is typically diagnosed in the 
grandfather of a boy with fragile X mental retardation [142, 143] and is associated with a 
reduced (in the 55–200 range) CGG expansion of the same gene. Clinical features of FXTAS 
include a progressive syndrome characterized mainly by tremor, cerebellar ataxia, peripheral 
neuropathy, and cognitive dysfunction [143]. MRI is an important diagnostic biomarker of 
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FXTAS which can present as a sporadic condition also in women [142, 143]. In particular, it 
demonstrates characteristic symmetric areas of T2 hyperintensity in the peridentate WM and 
middle cerebellar peduncles combined with symmetric signal changes in the periventricular 
cerebral WM and in the splenium of the corpus callosum (Fig. 2). There is a diffuse atrophy 
of the brain in the supra and infratentorial compartments, but the oval shape of the basis 
pontis is preserved [144]. Signal changes in the peridentate regions correlate with severity of 
ataxia, whereas signal changes in the splenium of the corpus callosum mark disease 
progression [143]. In addition, a voxel-based morphometry study indicated that gray matter 
loss in the vermis correlates with severity of motor symptoms, atrophy of the left amygdala 
correlates with increased levels of obsessive–compulsiveness and depression, and atrophy of 
the left inferior frontal cortex and anterior cingulate cortex correlates with poor working 
memory performance [145].
SPECT studies have revealed decreased uptake of the dopamine transporter and postsynaptic 
D2 receptors in the striata, accounting for the extrapyramidal symptoms often observed in 
patients with FXTAS [143, 144, 146].
To date, no longitudinal study has addressed the potentials of the above MR and nuclear 
medicine findings as progression or surrogate biomarkers of FXTAS.
 Section 9: Metabolic Cerebellar Ataxia (In Children)
A growing number of metabolic disorders that can entail cerebellar ataxia in childhood have 
been identified. These disorders usually implicate one or several metabolic pathways and are 
mainly characterized by: sporadic or hereditary genetic default causing enzymatic 
dysfunction, multisystemic impairments, variable age onset, nonspecific clinical expression, 
and an intermittent or progressive ataxic expression [147]. These disorders are often 
autosomic recessive but not exclusively. The majority of (mostly hereditary) metabolic 
cerebellar ataxia results from: alterations of amino acids (maple syrup urine disease, L-2 
hydroxyglutaric acidemia, isovaleric acidemia), lysosomal (Krabbe's disease, metachromatic 
leukodystrophy, Niemann–Pick disease type C, hexosaminidase A deficiency), peroxysomal 
(adrenoleucodystrophy, adrenomyeloneuropathy, Refsum disease) and glycosylation 
metabolisms, urea cycle, lactic acidosis (Leigh's disease), leukodystrophies (Canavan's, 
Alexander 's and hypomyelination disorders such as: Pelizaeus–Merbacher diseases, Pol-III 
related leukodystrophies: 4A, Cockayne syndrome, 18q-syndrome, fucoscidose, 
hypomyelination with atrophy of the basal ganglia and the cerebellum), mitochondropathy 
(MELAS, Kearns–Sayre syndrome), defects in gene encoding myelin protein and some 
miscellaneous troubles such as Wilson disease, Menkes disease, cerebrotendinous 
xanthomatosis, infantile neuroaxonal dystrophy, leukoencephalopathy with vanishing white 
matter, megalencephalic leukoencephalopathy with subcortical cysts and deficiencies in: 
biotine/biotinidase/holocarboxylase synthetase, sulfite oxidase and molybdenum, vitamin E 
or apolipoprotein B, for example [147–150].
Aside from clinical symptoms, the diagnosis of such (often rare) metabolic troubles relies 
principally on biochemical analysis of abnormal metabolites within urine, blood, 
cerebrospinal fluid or cellular culture (fibroblast), and mutation analysis of specific genes. 
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Magnetic resonance imaging (MRI) allows further morphological and biochemical 
characterization of such diseases.
Structural neuroimaging can detect numerous but heterogeneous subcortical or/and 
periventricular, supra- or/and infratentorial abnormalities in gray and white matter. The most 
affected brain structures are: cerebral cortex (thinning, atrophy), white matter (delayed 
myelination, cysts and abnormal FLAIR/T2-hyperintensity often due to demyelination), 
basal ganglia, especially the putamen (T2-hypointensity, atrophy, calcium deposits), 
thalamus, and some brainstem nuclei and tracts, while the most frequent but unspecific 
abnormality is leukoencephalopathy. It is noteworthy that white matter alteration can 
sometimes be a side effect of Wallerian degeneration accompanying gray matter 
abnormalities. In particular, T2-hyperintensity in white matter occurs during 
leukodystrophies, lysosomal and peroxisomal disorders, and mitochondropathy. 
Microstructural disorganization of the white matter, in particular caused by myelin injury 
can be assessed by diffusion-weighted imaging and quantified by the apparent coefficient of 
diffusion, radial or axial diffusivity, or fractional anisotropy. Other MRI sequences such as 
magnetic transfer magnetization, T1 and T2 relaxometry or tractography may also provide 
interesting information concerning white matter injury or recovery [148], while voxel-based 
morphometry and double-inversion recovery will give important information about gray 
matter. Contrast-enhancement in white matter or cerebellum is inconstant and is mainly 
observed in adrenoleukodystrophy and in Alexander disease, respectively. Concerning the 
cerebellum, a wide range of abnormalities has been observed from atrophy/hypoplasia, the 
most usual described sign, to T2-hyperintensity white matter or abnormal deep cerebellar 
nuclei. Although some differential regional patterns can be described in terms of anatomical 
localization or morphology, no one proves to be specific of a particular disease (diagnostic 
radiomarkers).
1H MR spectroscopy (MRS) can usefully complement MRI morphological data for 
diagnostic orientation [149, 151]. Lactate (anaerobic metabolism; doublet peak at 1.33 ppm) 
is commonly detected in mitochondropathies because of the disruption of the electron 
respiratory chain, but also in neuronal ceroid liposfuscinosis. More specific metabolites, and 
thus potential radiomarkers, can be also identified such as: galacticol (3.67/3.74 ppm) in 
galactosemia type 1, phenylalanine (7.37 ppm) in phenylketonuria, branched-chain amino 
acids and ketoacids (0.9 ppm) in maple syrup urine disease, increased N-acetyl-aspartate 
(NAA; 2.02 ppm) in Canavan's disease. Moreover, decreased NAA/choline ratio below 5.0 
might predict progression of X-linked adrenoleukodystrophy (evolution biomarker) [152]. 
Combining morphological and spectroscopic disease characteristics may help to reach a 
diagnosis. For instance, mitochondropathies (including Leigh's disease) can be suspected 
and discriminated by differential patterns of T2-hyperintensities and atrophy (subcortical 
white matter, basal ganglia, brainstem, colliculi, cerebellum including dentate nuclei, and 
less often thalami), lactate increase and stroke-like lesions [153]. Association of cerebellar 
atrophy and high lactate peak within the cerebellum seems strongly in favor of 
mitochondropathy-related cerebellar ataxia [154].
Therefore, the great heterogeneity and the nonspecificity of MR data, the existence of 
overlapping MRI expression of different diseases, the changing aspect of the brain lesions 
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with time and the small sample size of patient group due to the rarity of these diseases 
hamper to define the role of these potential radiomarkers for diagnosis and evolution 
assessment. However, some strategies, called pattern-recognition approach (PRA), have been 
developed to reduce progressively the list of possible diagnoses on the basis of well-defined 
anatomical criteria, which can be secondarily complemented by biochemical data [148, 
155]. For example, PRA will successively consider: gray and/or white matter involvement, 
subcortical and/or deep white matter involvement, symmetric or asymmetric lesions, basal 
ganglia and/or thalamus lesions, brainstem and cerebellar involvement, and so on [149]. This 
decision tree leads to group patients in distinct categories of better-circumscribed (but still 
too wide) diagnosis. Such classification can also benefit from advanced statistical methods. 
Steenweg et al. [155] classified successfully some hypomyelination disorders by applying 
multivariate and unsupervised hierarchical clustering to MRI characteristics of patients, such 
as T2-hyperintensity in white matter, basal ganglia, or pons, T2-hypointensity in the 
pallidum or cerebellar atrophy, for instance. It can, thus, be speculated that definition of such 
patterns of metabolic-related structural and biochemical abnormalities, enriched by new 
unconventional MRI sequences with possible quantification of MRI parameters and even by 
refined statistical analyses such as principal component analysis or hierarchical clustering, 
will enable to diagnose more and more specifically and unequivocally cerebellar metabolic 
ataxia in the future.
 Section 10: Sporadic Adult-Onset Ataxia of Unknown Etiology and 
Multiple Systems Atrophy
Multiple system atrophy (MSA) is a rare, sporadic, progressive, neurodegenerative disorder 
with a late onset (around 50 years). Clinical presentation mainly combines parkinsonism 
(akinesia, rigidity, tremor, postural instability), cerebellar ataxia (gait, speech and limb 
ataxia and gaze-evoked nystagmus), autonomic dysfunction (genito-urinary impairments, 
orthostatic hypotension), pyramidal syndrome and REM-sleep behavior disorder. MSA can 
be divided into MSA with parkinsonism predominance (MSA-P) and MSA with 
predominant cerebellar ataxia (MSA-C) [156, 157]. Cognitive and psychiatric troubles have 
been reported in MSA-C. Histopathological studies have identified distinctive 
oligodendroglial alpha-synuclein fibrillar intracytoplasmic inclusions associated with gliosis, 
and neuronal loss (apoptosis) within basal ganglia, cerebellum, pons, bulbar olivary nucleus 
and spinal cord (intermediolateral column). Neuroimaging may help to diagnose MSA and 
to characterize MSA-related anatomical abnormalities. The main MRI features of MSA 
(especially MSA-C) are: variable atrophy of cerebellum, middle cerebellar peduncle, pons, 
and putamen. Atrophy is also observed in frontal and insular cortices, medial part of the 
corpus callosum, and, at follow-up, in thalamus and caudate nucleus [158, 159]. More 
suggestive but not pathognomonic signs include: a cruciform T2 hyperintensity in the pons 
(“hot cross bun”) although found in other types of ataxia such as SCA, dorsolateral 
putaminal rim T2 hyperintensity (with increased MD in DTI), middle cerebellopeduncular 
and putaminal hypointensity. Postmortem MR-pathological correlations have established 
that: (1) cerebellar white matter atrophy was more severe than gray matter atrophy, (2) white 
matter T2 hyperintensities reflect demyelination and gliosis, and (3) dentate (and putaminal) 
hypointensities is linked to iron/ferritin deposition [160, 161]. T2-relaxometry can detect 
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increased relaxation rate R2 of morphologically normal putamen in MSA-C [162]. Several 
microstructural alterations within infra- and supratentorial structures have been determined 
using diffusion imaging and quantified by measures of ADC, MD, and FA. For instance and 
interestingly, the middle cerebellar peduncle displays: increased ADC and reduced FA (like 
the cerebellum) which is correlated with the Barthel index, rating the performance of daily 
activities and disease duration. DTI can detect early FA decrease and MD increase in pontine 
transverse and longitudinal fibers implicated in the “hot cross bun” but before its 
morphological expression [163]. DTI can also detect transverse pontocerebellar fibers and 
corticospinal degeneration more easily than T2 sequence [164]. Moreover, increased ratio of 
myo-inositol/creatine evaluated with 1H MR spectroscopy in the pons and medulla would be 
correlated with MSA-C severity. Increased cerebellar lactate peaks measured in 1H MR 
spectroscopy could contribute to distinguish SCA2 from MSA-C [165]. Moreover, SPECT 
and PET data point out possible: (1) hypometabolism in cerebellum, middle cerebellar 
peduncle, pons and putamen, (2) presynaptic nigrostriatal dopaminergic denervation, and (3) 
alteration of the cholinergic (Ch5–Ch6) projections from pedunculopontine and laterodorsal 
tegmental nuclei to the thalamus correlated with motor and disability impairments [166, 
167]. In conclusion, no MRI abnormality seems to be specific of MSA-C. A combined MRI 
and dopamine receptor imaging with [123I]-IBZM-SPECT reported a more severe cerebellar 
and brainstem atropy with MSA-C than MSA-P, while the loss of dopamine receptor was 
identical in both groups [168]. However, a combination of several signs such as cerebellar 
and pons atrophy and hypometabolism, “hot cross bun” and putaminal alterations may be 
very suggestive of MSA-C (diagnosis radiomarker). 3D-based MRI morphometry of the 
putamen and of the cerebellum can be used as a marker of disease progression [169].
Sporadic adult-onset ataxia of unknown etiology (SAOA) is characterized by a progressive 
ataxia occurring after 20 years (most often around 50 years) with a male preponderance and 
negative family history and without any causative genetic or acute disorders [170]. Clinical 
features can also include, more inconstantly, a pyramidal syndrome, polyneuropathy (one 
third of patients), and mild cognitive, autonomic, and motor impairments. Some 
proprioceptive deficits are frequently observed such as decreased vibration sense, or 
decreased/increased/absence of ankle reflexes. SAOA is accompanied by atrophy affecting 
mostly the cerebellar gray matter (especially superior vermis, and likely linked to Purkinje 
cell loss and gliosis), the white matter of the middle cerebellar peduncle and the outer edge 
of the pons. FDG-PET also revealed cerebellar, brainstem, and cerebral cortical 
hypometabolism. MRI pattern of the brain can be very close between SAOA and MSA 
[162]. However, brainstem atrophy is more prominent in MSA patients than in SAOA 
patients [171]. Moreover, in comparison with SAOA, MSA-C shows specific decreased 
regional blood flow in brain areas such as caudate tail, and lingual and fusiform cortices, and 
in the pons.
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Fig. 1. 
Schematic representation of the main sites of atrophy (in red) observed in SCA 1, 2, 3, 6, 7 
and 17 (A medulla oblongata; B pons, C cerebellum, D basal ganglia, E cerebral cortex) on 
sagittal view of the brain
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Fig. 2. 
a–l Diagnostic biomarkers of recessive and X-linked inherited ataxias on conventional MRI. 
Axial T1 weighted image (a) showing symmetrically thickened and parallel oriented 
superior cerebellar peduncles (black arrowheads) creating the “Molar Tooth” sign 
characteristic of Joubert syndrome and related disorders. Note also the small and 
dysmorphic vermis. Sagittal T1-weighted image (b) shows atrophy of the medulla and 
cervical spinal cord (arrow) in a case of Friedreich ataxia (FRDA). Axial T2*-weighted 
gradient echo image (c) confirms the decreased size of the cervical cord cross-section in the 
same disease and demonstrates symmetric hyperintensity of the posterior (white arrowhead) 
and lateral (black arrowheads) columns of the spinal cord (both images reprinted with 
permission from ref. [1]). Sagittal T1-weighted image (d) demonstrates widened vermian 
sulci in a patient with ataxia telangectasia (AT) consistent with a macroscopic pattern of 
cerebellar cortical atrophy (image reprinted with permission from ref. [1]). Axial T2*-
weighted gradient echo image (e) demonstrates multiple hypointense dots in the centrum 
semiovalis WM consistent with capillary telangectasias in another patient with AT (image 
reprinted with permission from ref. [128]). Axial (f) and sagittal (g) T2-weighted images in 
a patient with recessive spastic ataxia of Charlevoix-Saguenay (ARSA CS) show 
characteristic low signal intensity stripes (black arrows) corresponding to the corticospinal 
tracts in a bulky basis pontis. The white arrow in f and g indicates the hypointense medial 
lemniscus (both images reprinted with permission from ref. 129). Axial T2-weighted image 
(h) shows characteristic symmetric hyperintensity of the peridentate cerebellar WM in a 
patient with cerebroendineous xanthomatosis (image reprinted with permission from [130]). 
Axial T2-weighted image (i) in a patient with Fragile X-associated tremor ataxia syndrome 
(FXTAS) shows symmetric hyperintensity of the cerebellar WM which is accompanied in a 
coronal T2-weighted FLAIR image (l) by symmetric extensive areas of hyperintensity of the 
cerebral WM and of the splenium of the corpus callosum (arrow). Joubert Joubert syndrome 
and related disorders; FRDA Friedreich's ataxia; AT ataxia telangectasia; ARSACS 
autosomal recessive spastic ataxia of Charlevoix-Saguenay; CTX cerebrotendineous 
xanthomatosis; FXTAS Fragile X-associated tremor ataxia syndrome
Baldarçara et al. Page 34
Cerebellum. Author manuscript; available in PMC 2016 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor Manuscript
B
aldarçara et al.
P
age 35
Table 1
The spinocerebellar ataxias
SCA Gene/locus Mutation type Key symptoms in addition to 
cerebellar ataxia
MRI characteristics (atrophy)
Brainstem Pons Cerebellar hemispheres Vermis Basal ganglia Cortical areas
1 ATXN1/6p22.3 CAG repeat Dysphagia ++ ++ ++ ++ ++ +
2 ATXN2/12q24.12 CAG repeat Oculomotor symptoms ++ +++ ++ ++ (+) ++
3 ATXN3/14q32.12 CAG repeat Dystonia, parkinsonism, neuropathy ++ + ++ ++ +
4 /16q21.1 Unknown Sensory neuropathy + +
5 SPTBN2/11q13.2 Missense, n-frame deletion Nystagmus − − ++ ++ − −
6 CACNA1A/19p13.2 CAG repeat + + +++ +++ + (+)
7 ATNX7/3p14.1 CAG repeat Visual loss +++ ++ ++ +
8 ATXN8OS/13q21 CTG repeat Sensory neuropathy, spasticity − − ++ ++ −
9 Unknown Unknown Ophthalmoplegia, pyramidal and 
extrapyramidal signs
10 ATXN10/22q13.31 ATTCT Epilepsy − ++ ++
11 TTBK-2/15q15.2 Frameshift Nystagmus + +
12 PPP2R2B/5q32 CAG repeat Tremor − − + + − +
13 KCNC3/19q13.33 Point mutation Mental retardation + + +
14 PRKCG/19q13.42 Missense, deletion Myoclonus (+) ++ ++ − −
15/16 ITPR1/3p26.1 Missense, frameshift Tremor − − + ++
17 TBP/6q27 CAG repeat Dementia, psychiatric disorders +++ ++ ++ ++
18 /7q22-32 Unknown Sensory neuropathy, muscle atrophy + + (+)
19/22 KCND3/1p21-q21 Unknown Mental retardation + + (+)
20a /11q12 260 kb duplication Dysphonia, myoclonus ++ ++
21 /7p21.3-p15.1 Unknown Mental retardation + +
23 PDYN/20p13 Missense mutation Sensory neuropathy, pyramidal signs + +
24 /1p36 Unknown Pyramidal signs, axonal polyneuropathy
25 /2p21-13 Unknown Sensory neuropathy, gastrointestinal 
features
− − ++ ++
26 /19p13.3 Unknown − − ++ ++
27 FGF14/13q33.1 Point mutation Dyskinesia, metal retardation − − ++ ++ − −
28 AFG3L2/18p11.21 Missense mutation Oculomotor symptoms − − ++ ++ −
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SCA Gene/locus Mutation type Key symptoms in addition to 
cerebellar ataxia
MRI characteristics (atrophy)
Brainstem Pons Cerebellar hemispheres Vermis Basal ganglia Cortical areas
29 ITPR1/3p26 Missense mutation Cognitive impairment
30 /4q34.3-q35.1 Unknown
31 TK2, BEAN/ 16q21 TGGAA repeat Muscular hypotonia, auditory 
dysfunction
32 /7q32-q33 Unknown
34 /16p12.3-q16.2 Unknown Cutaneous plaques
35 TGM6/20p13 Missense mutation Oculomotor symptoms
36 NOP56/20q13 Repeat expansion Mus spasticity, fasciculations, atrophy of 
tongue and skeletal muscles
AFG3L2 ATPase family gene 3 like 2, ATXN ataxin, BEAN brain expressed associated with NEDD-4, CACNA1A calcium channel voltage-dependent P/Q type alpha 1A subunit, FGF14 fibroblast growth 
factor 14, ITPR1 inositol triphosphate receptor type 1, KCNC3 potassium voltage-gated channel Shaw-related subfamily member 3, KCND3 potassium voltage-gated channel subfamily D member 3, 
NOP56 ribonucleoprotein, PDYN prodynorphin, PPP2R2B serine/threonine-protein phosphotase 2A, PRKCG protein kinase C gamma type, SPTBN2 beta-III-spectrin, TBP TATA-box binding protein, 
TK2 thymidine kinase 2, TGM6 transglutaminase 6, TTBK2 tau tubulin kinase 2, − no atrophy, (+) mild/inconsistently reported, + mild atrophy, ++ moderate atrophy, +++ severe atrophy, blank not 
reported/unknown
aCalcifications of dentate nucleus
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Table 2
Genetic, clinical, laboratory and conventional MRI in most common recessive ataxias [modified from Anheim et al. (ref. 125)]
Disease Gene and protein Age at onset Key symptoms in addition to cerebellar 
ataxia
Laboratory findings Conventional MRI
Cerebellar ataxias with pure sensory neuropathy
 FRDA FXN frataxin 2–60 mean 16 Bilateral Babinski sign, scoliosis, square-wave 
jerks
GAA triplet repeat expansion in 
intron1 of FXN gene
Spinal cord and bulbar atrophy, 
symmetric T2 high signal in 
posterior and lateral columns of the 
spinal cord
 AVED TTPA alpha-tocopherol transfer 
protein
2–50 mean 17 Bilateral Babinski sign, scoliosis, retinitis 
pigmentosa
Decreased serum level of vitamin E Spinal cord atrophy
Cerebellar ataxia with sensorimotor axonal neuropathy
 AT ATM Ataxia Telangectasia mutated 2–3 Conjuctival telangectasias, dystonia, chorea, 
susceptibility to infections and cancer
Elevated serum Alpha-feto-protein, 
immunoglobulin deficiency, specific 
karyotype
Cerebellar atrophy brain T2 
hypointense dots
 AOA 1 APT aprataxin 1–20 mean 7 Oculocephalic dissociation, chorea, dystonia Elevated serum LDL cholesterol, 
low serum albumin
Cerebellar Atrophy
 AOA2 SETX senataxin 7–25 mean 15 Oculocephalic dissociation, chorea, dystonia Elevated serum Alpha-feto protein Cerebellar Atrophy
 ARSACS SACS sacsin Up to 12 mean 2 Spastic paraparesis, distal amyotrophy to 4 
arms, pes cavus, scoliosis
Atrophy of superior vermis, thinned 
corpus callosum, T2 hypointense 
stripes in a bulky pons, T2 
hyperintense rim around the 
thalami
 CTX CYP27 Sterol27 hydoxylase Childhood Sensory neuropathy, spasticity Elevated serum cholestanol Cerebellar atrophy, cerebellar and 
cerebral WM T2 hyperintensity
Cerebellar ataxia without neuropathy
 JSRD 10 causative genes encoding for 
proteins of the primary cilium (see 
ref [126])
Neonatal period Hypotonia, oculomotor apraxia, facial 
dysmorphism, irregular neonatal breathing, 
cognitive impairment, involvement of kidneys, 
liver, eyes
“Molar tooth”, vermal hypoplasia, 
enlarged IV ventricle and posterior 
fossa
 ARCA1 SYNE1 Spectrin 17–46 mean 32 Pure ataxia Cerebellar atrophy
 ARCA2 ADCK3 Aarf-domain containing 
Kinase 3
1–11 mean 4 Mental retardation, myoclonus, epilepsy, 
stroke like episodes
Elevated serum lactic acid, 
decreased coenzyme Q10
Cerebellar atrophy, stroke-like 
lesions
 NPC NPC1 2–30 Vertical supranuclear ophthalmoplegia, 
dystonia, cognitive impairment
Skin biopsy findings Variable cerebral and cerebellar 
atrophy
NPC1
NPC2
NPC2
AOA1 ataxia with oculomotor apraxia type 1; AOA2 ataxia with oculomotor apraxia type 2; ARCA1 autosomal recessiva cerebellar ataxia type 1; ARCA2 autosomal recessive cerebellar ataxia type 2; 
ARSACS autosomal recessive spastic ataxia of Charlevoix-Saguenay; AT ataxia telangectasia; AVED ataxia with vitamin E deficiency; CTX cerebrotendineous xanthomatosis; FRDA Friedreich's ataxia; 
JSRD Joubert syndrome and related disorders (ciliopathies); NPC Niemann–Pick type C
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